Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Natera's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $765 Mil. Natera's Total Assets for the quarter that ended in Dec. 2023 was $1,442 Mil.
Therefore, Natera's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.53.
The historical rank and industry rank for Natera's Equity-to-Asset or its related term are showing as below:
NTRA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.39 Med: 0.51 Max: 0.7
Current: 0.53
During the past 11 years, the highest Equity to Asset Ratio of Natera was 0.70. The lowest was -1.39. And the median was 0.51.
NTRA's Equity-to-Asset is ranked worse than 56.96% of 237
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58
vs NTRA: 0.53
Natera Equity-to-Asset Historical Data
The historical data trend for Natera's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Natera's Equity-to-Asset
For the Diagnostics & Research subindustry, Natera's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Natera's Equity-to-Asset falls into.
Natera Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Natera's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera (NAS:NTRA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Natera Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Natera's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTRA has been successfully added to your 